© 2024 BioMarin. All rights reserved.

Science | October 4, 2023

Targeting the Underlying Genetic Causes of Heart Disease

BioMarin researchers are leveraging the company’s expertise in translating genetic discoveries into potentially transformative medicines to address the root causes of certain forms of cardiovascular disease.

Our Motivation | September 25, 2023

RARE Scholars Program Provides Support to College Students Living with Genetic Conditions

The program was created to support U.S. college students living with one of four rare genetic conditions who have demonstrated exceptional leadership and engagement in school and community activities.

BioMarin Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions

For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to BioMarin, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]

Read More read more
Our Motivation | July 21, 2023

Raising a Child with Hemophilia: BioMarin Employee Jess Klass Shares Her Story

After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.

Science | June 29, 2023

FDA Approves BioMarin’s Gene Therapy for a Genetic Bleeding Disorder

We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]

Our Company | April 17, 2023

A Message from the Chairman and CEO

Dear Stockholder of BioMarin: In 2022, BioMarin achieved record revenue and pivoted to GAAP profitability, making it a truly transformational year for the company and laying the foundation for long-term growth. The global launch of VOXZOGO for children with achondroplasia helped drive that revenue growth. We believe conditional European approval of our gene therapy for […]